Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-06-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/17562864211022581 |
| _version_ | 1819065444078714880 |
|---|---|
| author | Hela-Felicitas Petereit Hayrettin Tumani Uwe K. Zettl |
| author_facet | Hela-Felicitas Petereit Hayrettin Tumani Uwe K. Zettl |
| author_sort | Hela-Felicitas Petereit |
| collection | DOAJ |
| first_indexed | 2024-12-21T15:46:33Z |
| format | Article |
| id | doaj.art-585b1ac23d99468db38876f1a7432c66 |
| institution | Directory Open Access Journal |
| issn | 1756-2864 |
| language | English |
| last_indexed | 2024-12-21T15:46:33Z |
| publishDate | 2021-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Neurological Disorders |
| spelling | doaj.art-585b1ac23d99468db38876f1a7432c662022-12-21T18:58:21ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28642021-06-011410.1177/17562864211022581Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesHela-Felicitas PetereitHayrettin TumaniUwe K. Zettlhttps://doi.org/10.1177/17562864211022581 |
| spellingShingle | Hela-Felicitas Petereit Hayrettin Tumani Uwe K. Zettl Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies Therapeutic Advances in Neurological Disorders |
| title | Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies |
| title_full | Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies |
| title_fullStr | Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies |
| title_full_unstemmed | Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies |
| title_short | Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies |
| title_sort | correspondence humoral immune response to covid 19 mrna vaccine in patients with multiple sclerosis treated with high efficacy disease modifying therapies |
| url | https://doi.org/10.1177/17562864211022581 |
| work_keys_str_mv | AT helafelicitaspetereit correspondencehumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies AT hayrettintumani correspondencehumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies AT uwekzettl correspondencehumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies |